RxDoctor Payments Data

Kelly Kompinski, PA

Medical · Naples, FLNPI 1083208003

Payments from drug & device makers

$4,343in general payments, 2019–2025

Across 168 payments — averaging $25.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$943
  • Mallinckrodt Hospital Products Inc.$681
  • Vifor Pharma, Inc.$455
  • Amgen$361
  • Inspire Medical Systems, Inc.$215
  • OPKO Pharmaceuticals, LLC$213
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$4,324100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,343 in reported general payments places this provider in the 85th percentile of 2,031 medical providers in Florida.

See all medical providers in Florida

Medicare billing

Part B allowed, 2024
$73,867
Medicare patients
321
Services billed
918

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol37$46,597
VeltassaPatiromer Calcium Sorbitex20$24,530
RayaldeeCalcifediol11$22,018
VelphoroSucroferric Oxyhydroxide12$20,050
KerendiaFinerenone12$13,545
LokelmaSodium Zirconium Cyclosilicate17$10,318
Calcitriol110$2,871
Calcium Acetate28$2,649
Sevelamer Carbonate13$1,355
Potassium Chloride21$1,207
Nifedipine ErNifedipine18$1,114
Losartan Potassium88$1,023
Amlodipine Besylate98$864
Hydralazine Hcl36$846
Torsemide20$694

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$212$56,91454 claims
OPKO Pharmaceuticals, LLCRayaldee$213$22,01811 claims
Fresenius USA Marketing, Inc.Velphoro$152$20,05012 claims
BayerKerendia$943$13,54512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,031 medical providers in Florida.

Other medical in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →